boothcheck doesn't label JAZZ overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. In the published model solve dated 2026-07-29T16:51:57.294Z, anchored at $257.10, JAZZ is priced for growth of +7.2%. Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium). The report narrative was composed 2026-06-27. The more the price assumes beyond what Jazz Pharmaceuticals plc has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.
Derived from Jazz Pharmaceuticals plc's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.